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Background: While BRCA mutation carriers possess a 20-40% lifetime risk of developing ovarian cancer, knowledge
about genetic modifying factors influencing the phenotypic expression remains obscure. We explored the
distribution of the MDM2 polymorphisms SNP309T>G and the recently discovered SNP285G>C in Norwegian
patients with BRCA related ovarian cancer.
Methods: 221 BRCA related ovarian cancer cases (BRCA1; n = 161 and BRCA2; n = 60) were tested for the MDM2
polymorphisms. Results were compared to healthy controls (n = 2,465).
Results: The SNP309G allele was associated with elevated OR for ovarian cancer in BRCA1 mutation carriers
(SNP309TG: OR 1.53; CI 1.07-2.19; p = 0.020; SNP309GG: OR 1.92; CI 1.19-3.10; p = 0.009; SNP309TG+GG combined:
OR 1.61; CI 1.15-2.27; p = 0.005). In contrast, the SNP285C allele reduced risk of BRCA1 related ovarian cancer in
carriers of the SNP309G allele (OR 0.50; CI 0.24-1.04; p = 0.057). Censoring individuals carrying the SNP285C/309G
haplotype from the analysis elevated the OR related to the SNP309G allele (OR 1.73; CI 1.23-2.45; p = 0.002). The
mean age at disease onset was 3.1 years earlier in carriers of SNP309TG+GG as compared to carriers of SNP309TT
(p = 0.068). No such associations were found in BRCA2 related ovarian cancer.
Conclusions: Our results indicate the SNP309G allele to increase and the SNP285C allele to reduce the risk of
BRCA1 related ovarian cancer. If confirmed in independent studies, this finding may have implications to counseling
and decision-making regarding risk reducing measures in BRCA1 mutation carriers.
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The prognosis of ovarian cancer is dismal with a 5 year
overall survival of 40-45%, as two thirds are diagnosed
with advanced disease, when the success of therapeutic
modalities is very limited [1-3]. The average annual inci-
dence rate is 10 per 100,000 women, and 8-13% carries a
germline mutation in the BRCA genes [3-7]. Meta-
analyses have revealed a wide variance in cumulative
ovarian cancer risk for BRCA mutation carriers, on aver-
age 40% in BRCA1 versus 11-18% in BRCA2 mutation
carriers [1,2]. BRCA1 related ovarian cancer are diag-
nosed at an earlier age than sporadic ovarian cancer* Correspondence: anne.dorum@medisin.uio.no
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reproduction in any medium, provided the orcases, while average age at diagnosis for BRCA2 muta-
tion carriers is similar to sporadic cases [2,3]. This leaves
BRCA1 mutation carriers in particular, with a difficult
decision regarding risk-reducing salpingo-oophorectomy
at young age, with impact on somatic, sexual and mental
morbidity [8-12]. Thus, identification of additional pre-
dictive factors modifying risk of disease may have impli-
cations to genetic counseling and timing of prophylactic
surgery.
Among potential risk modifying factors are SNPs alter-
ing the function of MDM2, the murine double-minute 2
homolog. MDM2 encodes an ubiquitin protein ligase tar-
geting the tumor protein p53, as well as other proteins
involved in cell cycle control like the retinoblastoma-
associated protein pRb [13,14]. The BRCA related high
grade serous carcinomas are characterized by a high levelal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cation ofMDM2 have also been considered an alternative
mechanism of p53 inactivation in cancers with wild-type
TP53 [16-19].
In 2004, Arnold Levine’s group published a newly dis-
covered polymorphism in the intronic P2 promoter of
MDM2, SNP309T>G (rs2279744; NM_002392.3:c.14
+309T>G) [20]. The SNP309G allele was shown to en-
hance MDM2 transcription by extending a Sp1 binding
site. Further, they reported SNP309G to be associated
with accelerated formation of soft tissue sarcomas
in individuals carrying a TP53 germline mutation
(Li-Fraumeni syndrome) as well as in sporadic soft tissue
sarcomas, lymphomas, colorectal cancer and estrogen
receptor-rich breast cancer [20-22]. However, subsequent
studies attempting to address the impact of SNP309 status
on cancer risk and age at disease onset in various solid
malignancies have produced conflicting results [23-27].
Recently, we reported a second polymorphism in
the MDM2 P2 promoter, SNP285G>C (rs117039649;
NM_002392.3:c.14+285G>C), located 24 bp upstream of
SNP309 [28]. Among cancer patients and controls tested
(n > 7,000), the SNP285C allele was not detected in any
individuals carrying the SNP309TT genotype. Thus, we
found the SNP285C variant in complete linkage disequi-
librium with the SNP309G allele, creating the distinct
SNP285C/309G haplotype (p < 1.0 x 10-10) [28].
SNP285C antagonizes the biological effect of SNP309G
by reducing the Sp1 ligand binding and reduces the risk
of several cancer types [28,29]. Interestingly, the
SNP285C/309G haplotype was detected in West Euro-
pean Caucasians, accounting for 11.7% of the SNP309G
alleles, but was absent in a Chinese population. Thus,Table 1 Genotypic and allelic frequencies of the MDM2 SNP28
ovarian cancer and healthy controls
SNP285 BRCA1 related BRCA2 rela
n (%) n
SNP285 GG 153 (95.0) 58
GC 8 (5.0) 2
CC 0 (0.0) 0
Total 161 (100) 60
G 314 (97.5) 118
C ** 8 (2.5) 2
SNP309 TT 52 (32.3) 22
TG 81 (50.3) 32
GG 28 (17.4) 6
Total 161 (100) 60
T 185 (57.5) 76
G ** 137 (42.5) 44
* Previously published data [28].
** Minor allele.SNP285C may be a confounding factor providing ethnic
disparity in evaluating potential impact of SNP309 on
cancer risk [30].
In our recent study, we reported an elevated risk of
sporadic ovarian cancer in Caucasians carrying the
SNP309G allele [28]. In contrast, we found the SNP285C
allele to reduce ovarian cancer risk by 37% in carriers of
the SNP285GC/309TG genotype versus carriers of the
SNP285GG/309TG genotype [28]. Here we report the dis-
tribution of the MDM2 SNP285G>C and SNP309T>G
polymorphisms in 221 Norwegian ovarian cancer patients
diagnosed with germline mutations in BRCA1 (n = 161)
and BRCA2 (n = 60). We compared the distribution of the
MDM2 polymorphisms SNP285G>C and SNP309T>G in
these patients to a group of 2,465 healthy controls [28].
Results
Effect of MDM2 SNP status on ovarian cancer risk in BRCA
mutation carriers
Among the 221 mutation carriers, 161 carried a germ-
line mutation in BRCA1 and 60 in BRCA2. Distribution
of the MDM2 promoter SNPs in BRCA carriers and
healthy controls are presented in Table 1, together with
previously published data of these SNPs in sporadic
ovarian cancer patients [28].
For SNP309, we found the frequency of the minor al-
lele, SNP309G, to be significantly higher in BRCA1 mu-
tation carriers (42.5%) than in healthy controls (34.3%;
p = 0.003). Notably, censoring individuals harboring
the SNP285C allele (previously shown to counteract
the effect of SNP309G) strengthened this association (p <
0.001). No such difference was observed for BRCA2 mu-
tation carriers (p > 0.5).5 and SNP309 in BRCA related ovarian cancer, sporadic
ted Sporadic disease* Healthy controls *
(%) n (%) n (%)
(96.7) 1260 (93.7) 2 274 (92.3)
(3.3) 82 (6.1) 183 (7.4)
(0.0) 3 (0.2) 8 (0.3)
(100) 1 345 (100) 2 465 (100)
(98.3) 2 602 (96.7) 4 731 (96.0)
(1.7) 88 (3.3) 199 (4.0)
(36.7) 515 (38.3) 1 072 (43.5)
(53.3) 661 (49.1) 1 093 (44.3)
(10.0) 169 (12.6) 300 (12.2)
(100) 1 345 (100) 2 465 (100)
(63.3) 1 691 (62.9) 3 237 (65.7)
(36.7) 999 (37.1) 1 693 (34.3)
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for ovarian cancer related to the SNP309TG and
SNP309GG genotypes (SNP309TG; OR 1.53; CI 1.07-2.19;
p = 0.020; SNP309GG; OR 1.92; CI 1.19-3.10; p = 0.009;
SNP309TG + GG combined: OR 1.61; CI 1.15-2.27;
p = 0.005) (Figure 1). Censoring individuals harboring the
SNP285C allele strengthened the association between
SNP309G status and increased ovarian cancer risk
(SNP309TG: 1.62; CI 1.12-2.33; p = 0.010; SNP309GG:
OR 2.18; CI 1.33-3.56; p = 0.003; SNP309TG + GG com-
bined: OR 1.73; CI 1.23-2.45; p = 0.002).
Regarding SNP285 status, the SNP285C/309G haplo-
type was detected in 8 out of 161 (5%) individuals carry-
ing a BRCA1 mutation and 2 out of 60 (3.3%) with a
BRCA2 mutation (Table 1). Although numbers are small,
the frequency of the SNP285C/309G haplotype among
carriers of the SNP309G was lower in BRCA1 mutation
carriers as compared to the frequency in healthy indivi-
duals (OR 0.50; CI 0.24-1.04; p = 0.057). The minor
allele frequency in this subgroup being 3.7% for BRCA1
mutation carriers and 7.1% for controls (p = 0.051).Figure 1 Impact of the MDM2 SNP309G and SNP285C on BRCA1 relat
odds ratio (OR) for ovarian cancer depending on MDM2 SNP status, error b
exact test.Effect of MDM2 SNP status on age at ovarian cancer onset
We further examined the effect of MDM2 SNP status
with respect to age at onset of ovarian cancer in BRCA
mutation carriers. The average age at diagnosis in
patients harboring the SNP309 genotypes TT, TG and
GG were 54.2, 51.2 and 51.8 years, respectively. When
censoring patients harboring the SNP285C/309G haplo-
type, the mean age at onset for the TT, TG and GG geno-
types were 54.2, 51.1 and 51.0 years, respectively. Thus,
carriers of the SNP309TG and GG genotypes were 3.1
years younger as compared to carriers of the SNP309TT
genotype (p = 0.068; Figure 2). The mean age at onset in
BRCA2mutation carriers did not differ from sporadic ovar-
ian cancer cases (59.6 versus 61.2 years), and we observed
no differences in age at onset related to SNP309 status.Discussion
Currently, little is known about factors acting as genetic
modifiers to ovarian cancer tumorigenesis. While several
studies have explored the effect of genetic variants oned ovarian cancer versus healthy controls. Bars indicate
ars indicate 95% CI and p-values are calculated by Fisher
Figure 2 Impact of the MDM2 SNP309 genotypes on age at ovarian cancer diagnosis in BRCA1 mutation carriers. The cumulative
percentage of individuals with the SNP309TT genotype (red triangles), the SNP309TG genotype (yellow diamonds) and the SNP309GG genotype
(blue squares) plotted against age at ovarian cancer diagnosis. The SNP285C/309G haplotype is censored in the dataset.
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tinct genetic variant that strongly predicts cancer risk in
these subgroups have been identified.
Studies addressing the impact of the MDM2 SNP309
status on risk of tumor development and age at onset in
different types of cancers have provided conflicting
results, with a trend for positive associations in Asians
but a lack of correlation in Caucasians [23,25-27]. While
the MDM2 SNP309G is an ancient polymorphism
detected in all ethnic groups examined so far, its fre-
quency display distinct ethnic variation [26], accounting
for 12.4% of the alleles in African Americans [32] con-
trasting about 34% in Caucasians [28,34] and 50-55% in
Asians [30-37]. In contrast, SNP285C is a more recent
polymorphism arising on the SNP309G allele and with a
distribution so far restricted to Caucasian populations
[28,30]. Previously, we found the SNP285C/309G haplo-
type to account for 11.7% of all the SNP309G alleles in
Western Europeans (British, Dutch and Norwegian
populations) but in less than 2% of Finns and absent in
healthy Chinese individuals [28]. In general, this distri-
bution has been confirmed by The 1000 Genomes Pro-
ject Consortium [38]. Thus, we hypothesize that the
occurrence of the SNP285C/309G haplotype may have
contributed to the conflicting results from studies
addressing the impact of SNP309 status on ovarian can-
cer risk in Caucasian populations.
Only a few studies have addressed the risk of ovarian
cancer with respect to SNP309 status. Three studies
(two Caucasian populations and one Japanese) reported
no association between SNP309G status and elevated
risk of ovarian cancer [37,39,40]. In contrast, the
SNP309G allele was found to be a potential protective
factor, associated with a reduced risk of ovarian cancer,
in a Chinese population [36]. However, these studies
included a limited numbers of patients (302 or less)without defined BRCA mutation status. In our previous
study on Caucasians evaluating nearly 2,000 sporadic
ovarian cancer cases and > 3,500 healthy controls, we
found an elevated risk of ovarian cancer in carriers of
the SNP309TG and SNP309GG genotypes [28]. How-
ever, we found a reduced cancer risk in carriers of the
SNP309TG genotype harboring the SNP285C/309G
haplotype.
To the best of our knowledge, only two studies have
addressed the impact of SNP309 on ovarian cancer risk
in BRCA mutation carriers. Yarden et al. [41] found the
SNP309GG genotype to be significantly associated with
risk of BRCA1 related ovarian cancer in Ashkenazi Jews
diagnosed before 51 years of age, while Copson et al.
[42] detected a non-significant trend for increased inci-
dence of ovarian cancer in British BRCA1 mutation car-
riers harboring the SNP309GG genotype. While the
distribution of the SNP285C allele in Ashkenazi Jews is
unknown, it occurs in the British population [28], thus,
it may have influenced the result reported by Copson
et al. [42], partly masking an effect of the SNP309G sta-
tus on ovarian cancer risk in this population.
Here, we report an elevated OR for ovarian cancer
in BRCA1 mutation carriers harboring a MDM2
SNP309TG or SNP309GG genotype. While the exact
OR values presented should be interpreted carefully due
to a limited number of observations, the results indicate
that SNP309 status may influence ovarian cancer risk
with OR to a similar extent in BRCA1 mutation carriers
as observed in sporadic ovarian cancer [28].
While the SNP285C/309G haplotype was observed in
13.1% of the SNP309G allele carriers in healthy controls
[28], the percentage in BRCA1 mutation carriers was
only 7.3% (OR 0.50; CI 0.24-1.04). The lower incidence
of the SNP285C/309G haplotype found in BRCA1 muta-
tion carriers with ovarian cancer may indicate a risk
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finding needs confirmation by independent studies.
A key feature in BRCA related breast and ovarian can-
cer is earlier age at onset as compared to sporadic dis-
ease, with the most distinct differences related to
BRCA1 mutations. When censoring patients harboring
the SNP285C/309G haplotype from our analyses, we
found BRCA1 related cancer cases carrying the
SNP309TG and SNP309GG genotypes to be on average
3.1 year younger at time of diagnoses as compared to
carriers of the SNP309TT genotype. Although this differ-
ence was of borderline statistical significance, it supports
the finding that the SNP309G allele promotes ovarian
tumorigenesis in BRCA1 mutation carriers. If confirmed
in other studies, this information may be useful for tim-
ing of risk reducing surgery in healthy BRCA1 mutation
carriers, as the age at onset in index cancer cases has
been found to predict individual risk [1].
Conclusions
In conclusion, we found the MDM2 SNP309 to increase
and SNP285C to reduce the risk of ovarian cancer in
BRCA1 related ovarian cancer. These findings may have
potential implications to genetic counseling and prophy-
lactic strategies in BRCA1 mutation carriers.
Methods
Ovarian cancer patients
In Norway, ovarian cancer treatment is centralized, and
The Norwegian Radium Hospital, covers 50% of the
population. A total of 221 BRCA mutation carriers were
identified among 1,566 patients diagnosed and treated
for invasive epithelial ovarian cancer; 161 carrying a mu-
tation in BRCA1 and 60 in BRCA2. All patients were
offered counseling and genetic testing irrespective of
family history of cancer, and participants signed a writ-
ten informed consent before testing. Pathology reports
were reviewed in all cases. Family members of mutation
carriers were offered genetic counseling, testing and
medical follow-up.
Controls
The 1,345 sporadic ovarian cancer patients (mutation
carriers excluded) and the 2,465 healthy controls used
for comparisons are previously described [28].
BRCA mutation analysis
All included patients were subjected to genetic testing in
the BRCA genes. Lymphocyte DNA was prepared from
peripheral blood by standard procedures (MagAttract
DNA Blood M48 Kit, Qiagen), amplified by polymerase
chain reaction (HotMaster Taq DNA Polymerase, 5
PRIME) and subjected to subsequent analysis. Mutation
analysis was performed with the application of differentscreening techniques (fragment length analysis with
fluorescent primers, MLPA analysis (SALSA MLPA kits,
MRC Holland) and direct sequencing (BigDye Termin-
ator Cycling Sequencing Kit, Applied Biosystems) to de-
tect genetic variations in the BRCA genes. All detected
mutations were confirmed by independent DNA extrac-
tions, PCRs and sequencing reactions.
MDM2 promoter genotyping
A region of the MDM2 P2 promoter covering SNP285
and SNP309 was amplified by PCR and sequenced as
previously described [28].
Statistical analysis
Statistical analyses were performed using the SPSS soft-
ware package (version 15.0.1). Differences regarding
SNP frequency were evaluated by Chi square and Fisher
exact tests, and MDM2 SNP distribution among ovarian
cancer patients and healthy controls presented as odds
ratio (OR). Differences in age at onset were evaluated by
Kruskal-Wallis and Mann–Whitney rank tests. All p-
values are given as two-sided and confidence intervals
(CI) for odds ratios are given as 95%.
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